CorMedix Inc. (NYSEAMERICAN:CRMD) saw unusually-high trading volume on Monday . Approximately 2,052,908 shares traded hands during trading, an increase of 203% from the previous session’s volume of 678,508 shares.The stock last traded at $0.61 and had previously closed at $0.56.

CRMD has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of CorMedix from a “buy” rating to a “hold” rating in a research note on Thursday, September 7th. HC Wainwright set a $4.00 target price on shares of CorMedix and gave the company a “buy” rating in a research note on Monday, October 16th.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of CorMedix by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 35,148 shares in the last quarter. Susquehanna International Group LLP increased its stake in CorMedix by 11,785.4% during the 2nd quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock valued at $886,000 after purchasing an additional 2,085,670 shares in the last quarter. Elliott Management Corp increased its stake in CorMedix by 177.8% during the 2nd quarter. Elliott Management Corp now owns 4,166,868 shares of the biotechnology company’s stock valued at $1,785,000 after purchasing an additional 2,666,668 shares in the last quarter. Finally, Sabby Management LLC bought a new stake in CorMedix during the 2nd quarter valued at about $1,818,000.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/12/11/cormedix-crmd-sees-large-volume-increase-2.html.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Receive News & Ratings for CorMedix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.